We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+26.26%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$858M
AUM Growth
-$99.6M
Cap. Flow
-$189M
Cap. Flow %
-21.99%
Top 10 Hldgs %
70.19%
Holding
45
New
7
Increased
7
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.5M
2
TSRO
TESARO, Inc.
TSRO
+$26M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$25.9M
4
XNCR icon
Xencor
XNCR
+$23.4M
5
DVAX
Dynavax Technologies
DVAX
+$17.4M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$66.8M
2
INSM icon
Insmed
INSM
+$46.6M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$36.4M
4
NVAX icon
Novavax
NVAX
+$35.3M
5
XOMA
Xoma
XOMA
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 73.69%
2 Miscellaneous 26.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
26
MacroGenics
MGNX
$257M
$5.47M 0.64%
+199,398
New +$5.22M
EYPT icon
27
EyePoint Inc
EYPT
$316M
$4.71M 0.55%
+118,761
New +$3.85M
DYAX
28
CALL
DELISTED
DYAX CORPORATION
DYAX
$3.77M 0.44%
500,000
– –
LITS
29
Lite Strategy Inc
LITS
$37.1M
$3.27M 0.38%
+20,417
New +$3.49M
CHTP
30
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$2.96M 0.34%
+666,667
New +$2.25M
FBIO icon
31
CALL
Fortress Biotech
FBIO
$83M
$2.63M 0.31%
66,667
– –
ACHV icon
32
Achieve Life Sciences
ACHV
$753M
– –
-347
Closed -$7.08M
AGIO icon
33
Agios Pharmaceuticals
AGIO
$1.96B
– –
-70,000
Closed -$1.96M
INSM icon
34
Insmed
INSM
$26.2B
– –
-2,983,319
Closed -$46.6M
MYGN icon
35
Myriad Genetics
MYGN
$371M
– –
-450,000
Closed -$10.6M
OMER icon
36
Omeros
OMER
$1.24B
– –
-1,055,311
Closed -$10.3M
TGTX icon
37
TG Therapeutics
TGTX
$8.12B
– –
-600,000
Closed -$3.02M
XOMA
38
DELISTED
Xoma
XOMA
– –
-345,776
Closed -$31.1M
LUMO
39
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-204,477
Closed -$36.4M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-3,045,380
Closed -$16.9M
AMPE
41
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-4,419
Closed -$9.94M
EPZM
42
DELISTED
Epizyme, Inc
EPZM
– –
-10,000
Closed -$400K
KERX
43
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-1,000,000
Closed -$10.1M
KERX
44
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-2,391,261
Closed -$24.1M
HPTX
45
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
– –
-902,858
Closed -$23.6M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, RA Capital Management held 45 positions worth $858M, down 10% from $958M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $189M in Q4 2013, closing 14 positions and reducing 8 holdings. Its most notable exit was Insmed, an estimated $46.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

Against the trend, RA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $51.8M.

  • RA Capital Management's largest Q4 2013 buy was IVERIC bio, Inc. Common Stock: 1,600,455 shares worth $51.8M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q4 2013, an estimated $25.9M increase.
  • RA Capital Management's biggest Q4 2013 reduction was DYAX CORPORATION, cutting an estimated $66.8M.
  • RA Capital Management fully exited Insmed in Q4 2013, selling an estimated $46.6M.
  • RA Capital Management's ten largest holdings make up 70% of its $858M portfolio in Q4 2013.
  • RA Capital Management opened 7 new positions and closed 14 in Q4 2013.
  • RA Capital Management's portfolio value fell 10% quarter-over-quarter to $858M.

Based on RA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.